in October 2011, the USPSTF updated their recommendation to a D grade for PSA screening in all men, discouraging the practice altogether 3 . The reasons why a guideline group would recommend against PSA screening as a response to the nonoptimal screening and treatment practices seen in the USA -including excessive rates of screening among older men with limited life expectancy or multiple comorbid ities, who are unlikely to benefit -are understandable [6] [7] [8] . These men have been screened at rates equal to, or even in excess of, those of younger, healthier men, who are more likely to benefit from PSA testing, early detection, and treatment. Similarly, men with low-risk prostate tumours have been excessively overtreated in the USA over the past two decades 9 contributing to treatment-related harms and deterioration in quality of life. The use of active surveillance for low-risk tumours has been increasing, but this change has been relatively recent, with 40% of men with low-risk tumours managed conservatively in 2010-2013, compared with only ~10% between 1990 and 2009 (REF. 9 ).
The USPSTF recommendation is just one of several guidelines for PSA screening. Others include those issued by the American Cancer Society, American Urological Association, European Association of Urology, National Comprehensive Cancer Network, and American College of Physicians. Most guidelines emphasize shared decisionmaking 10 ; however, they diverge in areas such as age to start and stop screening, screening intensity, and the PSA threshold at which to refer a patient for prostate biopsy [10] [11] [12] [13] . Many of the guidelines agree that screening does not benefit men with a life expectancy of <10 years 12, 13 . In this Review, we examine temporal and regional trends in PSA screening and prostate cancer incidence in the USA that have emerged in the years following the 2012 USPSTF recommendation against PSA screening in all men. We also evaluate how this recommendation has affected physician and patient attitudes about PSA screening. Finally, we discuss the implications of these trends with respect to PSA screening practice and prostate cancer outcomes, and consider the future of screening for prostate cancer.
Overall testing patterns
Since its inception in the late 1980s, PSA screening has been widespread in the USA as a method for secondary prevention of prostate cancer and for reducing the risk of prostate-cancer-specific death 14 . However, the literature since 2012 suggests that PSA screening rates have decreased in response to the USPSTF recommendation 6, 7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] 
. A study conducted by Li and colleagues 20 , using the National Health Interview Survey (NHIS), reported that screening rates dropped from 31.8% in 2008 to 24 .2% in 2013. In accordance with these data, a cross-sectional study by Abdollah et al. 15, 16 that employed the 2012 and 2014 Behavioural Risk Factor Surveillance System (BRFSS), investigated how many men aged ≥50 years underwent PSA testing in the previous year. They demonstrated a nationwide decrease, from 34.9% (95% CI 34. 4-35.4) in the 2012 survey (reflecting screening rates in 2011) to 31.9% (95% CI 31.4-32.4) in the 2014 survey (reflective of 2013). Furthermore, Jemal et al. 19 analysed Surveillance, Epidemiology and End Results (SEER) data, also on men ≥50 years, who responded to an NHIS questionnaire and found an 18% (95% CI [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] relative decrease in PSA testing, from 37.8% in 2010 to 30 .8% in 2013. In another study using data from the NHIS, Sammon et al. 23 showed that 46.5% of men aged ≥50 years received screening in 2010 compared with 41.3% in 2013 (P <0.001).
Several studies have investigated whether PSA screening rates following the 2012 USPSTF recommendation varied by geographical region. According to data from Abdollah and colleagues 15 , many states experienced a decrease in PSA screening rates after the 2012 USPSTF recommendation. However, screening rates were heterogeneous between states, for unknown reasons 15 . Using a database from a cohort in Southeastern Michigan, Rezaee et al.
22 generated a linear model to ascertain changes in PSA testing and transrectal ultrasonography usage before and after 2012. Their study, which included 3,647 men aged ≥50 years, showed that average PSA screening rates decreased in the post-USPSTF period.
PSA testing by age group
Screening is often indicated for men aged 55-69 years 11, 13 owing to the results of the ERSPC trial, which showed that PSA screening was associated with a significant reduction in risk (P = 0.001) of prostate cancer mortality in this population 1 . Other guidelines recommend starting screening at 45 years 12, 34, 35 , owing to evidence that an elevated baseline PSA level at this age can be predictive of future lethal disease 36 . Despite these discrepancies, when PSA screening rates following the 2012 recommendation were stratified by age, decreases were noted across all groups, including those for whom screening is likely to be most beneficial 6, 18, 20, 21, [24] [25] [26] 29, [31] [32] [33] . For men aged 50-59 years, rates of screening decreased from 33.2% to 24.8% from 2010-2013; for men 60-74 years, screening decreased from 51.2% to 43.6%, and for men ≥75 years, screening decreased from 43.9% to 37.1% 6 . In a review of 2008-2012 data from a large health-care system in northeastern Ohio, the greatest decrease in screening was observed in men 50-59 years. This reduction was statistically significant (P <0.001) after the first publications of ERSPC and PLCO in 2009, but not statistically significant in the post-2012 period 17 . Similarly, in a study analysing the influence of the 2009 ERSPC and PLCO
Key points
• In 2012, the United States Preventive Services Task Force (USPSTF) issued a Grade D (against screening) recommendation for PSA screening for prostate cancer • Rates of PSA screening, prostate biopsy and overall prostate cancer incidence declined in the first few years after the recommendation, with a shift towards higher grade and stage of prostate tumours at the time of detection • Despite the recommendation, some physicians report ongoing willingness to screen appropriately selected men, and many men report that they intend to continue to ask for the PSA test from their doctor • Increased follow-up durations are needed in order to understand whether the decreased rates of PSA screening will effect prostate cancer metastasis and mortality publications, Zeliadt et al. 29 reported that PSA screening between 2005 and 2010 decreased by 3% and 2.7% in men aged 40-54 years and 55-74 years, respectively, with a continuing decline in men ≥75 years that likely began following the USPSTF's 2008 recommendation against screening in this population.
In a more in-depth study, Sammon et al. 23 23 . Likewise, examination of population-based institutions in Michigan and Massachusetts from before the USPSTF recommendations showed that PSA testing rates in these states were 27-32% in 2000-2008, which subsequently decreased to a mean of 25% in 2009-2012 and 23% in 2013-2014. Stratification by age showed similar decreases in both the 55-69 years and ≥70 years age groups, at 33% and 31%, respectively. In a population-based cohort of privately insured patients, PSA screening rates did not change between 2008 and 2013 for patients aged 50-74 years (P >0.17), but decreased significantly for men ≥75 years (P = 0.04) 37 . Possible reasons for the discrepancies between studies are the source of data, cohorts with higher socioeconomic status, and level of education -hence different views towards preventive health care.
A 25% decrease in PSA screening has also been reported in African-American men and those with a family history of prostate cancer, who have an inherently increased risk of developing the disease 18 . Nevertheless, in a separate study, a review of 2012 BRFSS data showed that, despite the USPSTF recommendation, AfricanAmerican men still had higher odds of being screened compared with white men (OR 1.51; 95% CI 1.37-1.67) 27 . Moreover, one study conducted in a group of primary-care clinics concluded that the USPSTF guideline was not followed in such a way that the no-screening message was brought equally to all men. In fact, men with a family history were more likely than those without family history and African American men less likely to be screened than non-African-American men, and older men >70 years received more balanced counselling 38 .
PSA testing patterns by specialty PSA screening is often part of the routine physical examination, meaning that primary-care providers are largely responsible for initiating discussions about screening. Measuring the proportion of screening by specialty, Aslani et al. 17 showed that 64.9% of PSA tests were ordered by internists and 23.7% by family physicians, whereas only 6.1% were ordered by urologists and 1.3% by haematologists and/or oncologists in their regional hospital network between 2008 and 2012. After 2012, PSA screening rates decreased in all subgroups but most notably in urologists (P <0.05). Several studies examined differences in PSA test ordering among primary-care providers 21, 25, 26, 28, 31, 32, 39 . Using the National Ambulatory Medical Care Survey (NAMCS), Shoag et al. 25 showed • Inconsistent changes in PSA screening practices among high-risk men 18, 27, 38 Other tests and clinical work-up • Fewer DREs 25, 26, 40 • Fewer clinical work-ups for elevated PSA 22, 42, 43 • Urology referrals at higher PSA values 39, 43, 45 • Increased use of risk-stratified screening approaches 32, 46 Biopsy patterns • Fewer biopsies performed 30, 42, 43, [47] [48] [49] [50] [51] • No change in biopsy rates 22, 46, 52 • More positive biopsies 43, 64, 65 • Fewer low-risk/grade cancers detected 47, 48, 58, 63 • • Majority pro-screening; anti-screening opinions increased 70 that rates of PSA testing and digital rectal examination (DRE) by primary-care providers fell 39% and 64%, respectively, after the 2012 USPSTF recommendation. A similar trend was suggested by Yates et al. 40 in a survey of 73 primary-care providers, among whom 75% changed their PSA screening practice, mainly offering fewer PSA tests; however 50% still offered PSA to men >70-years. When asked, "has the USPSTF statement in 2012 changed your practice of recommending DRE?, " 36% reported performing fewer DREs.
PSA testing by primary-care providers decreased from 8.6% in 2011 to 7.6% in 2012 (P = 0.0001); stratification by age revealed the largest decreases in men 40-49 years (5.6% to 4.6%, P = 0.004) and 70-79 years (7.9% to 6.2%, P = 0.0074) 32 . Interestingly, the likelihood of receiving PSA screening in the primary-care setting seems to be affected by whether the man is a 'new' patient versus an 'established' patient. Among established patients, Miller et al. 21 identified a 9.9% decrease in screening (P <0.01) from May 2010 to April 2014, most notably for patients in their 60s (10.8% decrease, P <0.01) and those aged >70 years (18.2% decrease, P <0.01). By contrast, PSA screening in new patients underwent a 4.1% overall reduction, with a 27.6% decrease for patients >70 years but a 12.3% increase for patients 50-59 years (P <0.01).
Interestingly, the USPSTF recommendation seems to have differentially affected PSA testing practice among physicians in different specialties. In one study within a network of seven hospitals, of which six were considered suburban or rural, the most substantial decrease in PSA test ordering was among urologists 17 ; no significant change was observed among family physicians. Conversely, a separate study showed that, using the 2010 and 2012 NAMCS, PSA testing substantially decreased from 36.5% to 16.4% (P = 0.009) within the primary-care setting, but decreased nonsignificantly in the urology setting, from 38.7% to 34.5% (P = 0.089) 28, 41 . This discrepancy might be reflective of differences in practitioner attitudes and/or geographic variation between institutions. Similarly, Cohn et al. 32 analysed data from the North Shore University health system enterprise data warehouse and noted a decrease in PSA testing in the primary-care setting, predominantly in older men (aged 70-79 years; 9.1% before the recommendation versus 5.6% after, P <0.001) and in men without a history of an elevated PSA. Moreover, a study evaluating changes in PSA testing practice between urologists and radiation oncologists, who both routinely diagnose and treat prostate cancer in the USA, in response to the USPSTF recommendation showed that urologists were more likely than radiation oncologists to recommend screening for men [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] 43, 44 . Although a study by Hutchinson and colleagues 39 suggested that PSA testing rates did not change at their institution, they did show that primary-care providers were referring patients at increasingly higher PSA values -an average of 2.56 ng/ml in 2012, 2.72 ng/ml in 2013, 3.06 ng/ml in 2014, and 3.84 ng/ml from 2015 onwards. This change could affect stage and grade at diagnosis. Dalela et al. 45 tracked risk-group stratification in the National Cancer Database (NCDB), noting that 13.9% of patients had a PSA level >20 ng/ml in 2013 versus 11.5% in 2011. Likewise, within a large urology practice reported by Gaylis and colleagues 43, 44 , median prebiopsy PSA levels steadily increased from 7.0 ng/ml to 8.1 ng/ml (P = 0.0006) and the proportion of men with PSA levels >10 ng/ml increased from 28% to 38% from 2011 to 2014.
Despite these studies suggesting a trend toward indiscriminate decreases in screening, others suggest the adoption of more risk-stratified approaches. Rescreening rates at one institution decreased significantly in patients with a highest previous PSA value <2.5 ng/ml (REF. 32) (P <0.001). However, a second study showed that more patients received PCA3 testing (27% versus 11%; P <0.01) and more received repeat PSA testing (82% versus 72%; P = 0.02) 46 after the 2012 recommendation.
Prostate cancer incidence

Biopsy rates
Considering the widespread reduction in rates of screening after the USPSTF recommendation, the concomitant reporting of lower rates of prostate biopsy is unsurprising, with decreases of 13-34% 30, 42, 43, [47] [48] [49] [50] [51] . In a large hospital network in Toronto, the median number of prostate biopsies per month decreased from 58 (IQR 54.5-63.0) to 35.5 (IQR 27.0-41.0) 48 between October 2008 and June 2013. As prostate biopsies can be diagnostic or to investigate possible recurrence after treatment, first-time biopsies were analysed separately; these also decreased during the same period, from a median of 42.5 (IQR 37.5-57.5) to 24.0 (IQR 19.0-32.5).
However, other studies showed no such declines. Although Rezaee and colleagues 22 reported a drop in PSA utilization between the years 2010-2011 and 2013-2014 (P <0.001), 80% of men still underwent PSA testing and no significant decline in biopsy utilization was noted 22 . Similarly, Perez et al. 46 noted that, although urologists at their institution were recommending biopsy to fewer new patients (16% before the recommendation versus 24% afterwards; P = 0.03), the overall proportion of biopsies performed before and after the recommendation was unchanged, at 44.3% and 45.5%, respectively (P = 0.8) 46 . One study from a large community urology practice reported no change -or <5% change per year -in the number of biopsies in the first 3 years after the USPSTF statement in 2012 (REF. 52 ). Overall, PSA testing rates decreased, but the practice did not cease, and biopsies were, therefore, still performed when indicated, especially when PSA testing rates were still high and among men undergoing repeat biopsy.
Overall prostate cancer incidence
The PSA era in the USA, beginning in the with its commercial introduction in 1986 and landmark studies in the early 1990s showing that PSA outperforms DRE as a screening test 53 , caused an initial rapid surge in prostate cancer incidence in the USA; according to SEER data, age-adjusted prostate cancer incidence increased by 82% from 1986 to 1991 in men aged ≥65 years 54 . However, prostate cancer incidence has been declining since the early 1990s, that is, even before the USPSTF recommendations in 2008 and 2012, and levels are now below prePSA-era rates 55 . This reduction is likely to be multifactorial, and associated with the rate of dissemination of PSA screening, lead times, secular trends in the absence of screening and overdiagnosis 56 , and a combination of early detection of tumours at a curable stage and overdetection of indolent disease. The initial trend peak in prostate cancer incidence has been interpreted as a "harvest effect" -that is, a depletion of previously undiag nosed and accumulated cases from the pool of preva lent preclinical cases from previous years. In addition, the use of transurethral resection of the prostate (TURP) for benign prostatic hyperplasia increased during the 1980s, with an associated increase in incidental prostate cancer detection on pathology review of the TURP specimens 57 . The decline in prostate cancer incidence in the late 1990s represents a clearing out of prevalent cases 55 . Since the 2008 USPSTF recommendation against PSA testing in men over the age of 75 years and the conflicting publications from ERSPC and PLCO, decreased rates of PSA screening have likely contributed to the observed decreased incidence of prostate cancer 19, 48, 58, 59 . SEER data indicate that, between 2011 when the USPSTF released their draft recommendation and 2013, prostate cancer incidence declined each year in comparison with the preceding year in all ages and races (FIGS 1-3) Using data from the NCDB, Barocas et al. 58 showed that in the year after the release of the 2011 USPSTF recommendation draft, prostate cancer diagnoses fell by 12.2% in the first month (P <0.01) and continued to decrease by 1.8% per month (P <0.01), resulting in an overall decline of 28%. This decrease translated to 1,363 fewer cases the first month and a further decline of 164 cases per month. By contrast, colon cancer diagnosis rates remained stable over the same period 58 . Likewise, men were less likely to be diagnosed with prostate cancer (OR 0.81, 95% CI 0.74-0.89) after the 2012 USPSTF recommendation 22 . Assuming no change in the natural history of prostate cancer itself, this decline in incidence can probably be attributed to lower rates of screening.
Incidence by stage
By analysing stage-specific rates of prostate cancer incidence between 2008 and 2012, Jemal et al. 61 showed that declines in incidence in men aged >50 years were largely among localized/regional cancers. The decrease in earlystage prostate cancer incidence persisted throughout 2013, but at a slower pace 61 . Distant-stage cancer rates remained stagnant except in men aged ≥75 years, in whom the incidence per 100,000 men increased significantly, from 57. . These findings cannot be entirely explained by reactions to the USPSTF recommendations, as the trends began before they were announced. Plausible explanations are multifactorial and the authors speculate on other influences in screening guidelines and practices, alterations in the biological aggressiveness of prostate cancer or, less likely, changes in case ascertainment 62 . Using the same methodology, Herget and colleagues 63 analysed data from SEER Nature Reviews | Urology between 2007 and 2012 and found a −19.6% APC in prostate cancer incidence beginning in May 2011 (before the USPSTF draft release in October 2011), a decline that was observed in all age groups, with the greatest decline observed in men aged ≥75 years, following the USPSTF 2008 recommendation. Declines were noted in lowgrade and high-grade tumours as well as stage I/II and III tumours. The authors of the study considered changes in risk factors of population demographics less likely to explain changes in prostate cancer incidence than changes in screening practices. These trends also coincide with the simultaneous publications of the two conflicting results of randomized trials of PSA screening, ERSPC and PLCO, which published their first results in 2009 (REFS 29, 63) . In summary, the early temporal trends in stage at diagnosis after the USPSTF 2012 recommendation are multifactorial and difficult to interpret with short follow-up duration, and a trend towards higher stage at diagnosis (reverse stage migration) has been reported.
Biopsy outcomes and risk groups at diagnosis.
Several studies have evaluated whether the 2012 USPSTF recommendation catalysed a shift towards more adverse biopsy findings, such as advanced clinical TNM stage and higher Gleason grade disease. Three studies reported that the rate of positive biopsies increased following the recommendation to cease screening: Gaylis et al. 43 showed an increase from 46% to 50%, Rosenberg and colleagues 64 reported a 29% increase, and Olsson et al. 65 noted annual increases, from 39% in 2010-2011 to 41 .4% in 2013, 42.6% in 2014 (P <0.001), and 46% in 2015 (P <0.001). Similarly, the number of biopsies reported at Virginia Mason Hospital in Seattle containing no prostate cancer and Gleason score 6 disease decreased by 36% and 15%, respectively 47 .
Cessation of PSA screening might reduce diagnosis of low-risk cancers that are unlikely to be fatal; however, concerns have been raised that the USPSTF's blanket rejection could similarly decrease detection of more aggressive cancers for which intervention would have been indicated. Newly diagnosed cases of prostate cancer stratified by risk group within the University Health Network in Toronto showed that the median number of low-risk cancer diagnoses decreased from 8.5 (IQR 6.5-10.5) to 5.5 per month (IQR 4.0-7.0; P = 0.012), and the median number of intermediate-risk and high-risk cancers (Gleason 7-10) decreased from 17.5 (IQR 14.5-21.5) to 10.0 (IQR 9.0-12.0; P <0.001) 48 . Similarly, Barocas et al. 58 used data from the NCDB and reported significant decreases in prostate cancer incidence across all D' Amico risk groups 1 year after the USPSTF recommendation: low-risk, intermediate-risk, and high-risk disease decreased by 37.9%, 28.1%, and 23.1%, respectively (P <0.01 for the monthly slope change after the guideline change relative to before the guideline change), with an additional slight but nonsignificant decrease in nonlocalized disease 58 .
Conversely, other studies demonstrate migration towards increased proportions of higher-risk tumours at diagnosis. Dalela et al. 45 also used NCDB data and showed a decrease in low-risk cases, from 31.9% in 2011 to 25.9% in 2013, and a corresponding increase in intermediate-risk (43.5% to 45.1%) and high-risk (24.5% to 29%) cases (all P <0.001) 45 . Additionally, men in their cohort were less likely to be diagnosed with low-risk disease (OR 0.74) and slightly more likely to be diagnosed with intermediate-risk or high-risk disease (OR 1.05,1.22, respectively). In a study of 580 men in the Inland Empire Health Plan, an increase in high-grade disease at diagnosis was noted within 3 years of the 2012 recommendation (75.5% after 2012 versus 56.5% before 2012; P = 0.01), Nature Reviews | Urology together with an increase in direct medi cal costs of care 44 reported from a large urology practice that the proportion of Gleason score of 8 or higher rose from 21.4% to 30.4% (P <0.001) from year one to year three over a three-year period coinciding with the USPSTF 2012 recommendation. 
Attitudes towards PSA screening
Patient attitudes
Men's reactions to the 2012 USPSTF recommendation and whether it affected their perceptions about PSA screening have been examined in several studies. Squiers et al. 68 surveyed 1,089 men aged 40-74 years to determine if they agreed with the recommendation and would adhere to it. Although 62% of respondents agreed with the recommendation, only 13% intended to actually cease screening; 54% intended to continue and 33% were undecided. Patients more likely to continue screening were AfricanAmerican, those who had received a PSA test within the past 2 years, had a high income, and a moderate-to-high level of concern about developing prostate cancer. Similarly, examination of 54 patient questionnaires from primary care and urology clinics taken before and after reading opposing PSA screening guidelines (AUA and USPSTF) showed that 52% of patients initially reported good or very good comprehension of PSA screening recommendations. After they read the guidelines, claims of good or very good understanding increased to 65%, and support for PSA screening decreased nonsignificantly, and remained high (87% to 80%; P = 0.6) 69 . Prabhu et al. 70 at New York University undertook a novel approach, amassing all prostate-cancer-related Twitter posts in the 24-hour period after the release of the draft recommendation in October 2011 and final recommendation in May 2012. The draft version generated 2,042 tweets and the finalized version generated 5,357; however, only a small minority (9% and 4%, respectively) articulated an opinion about screening. Interestingly, although the majority of opinionated tweets were pro-screening, the proportion of anti-screening tweets increased from 22% in 2011 to 32% in 2012 (P = 0.03).
Primary-care physician attitudes
Three studies have examined the extent to which the 2012 USPSTF recommendation influenced primary-care providers' attitudes towards PSA screening. All three showed that primary-care providers were largely informed about the guideline. Two studies, by Tasian et al. 71 and Rosenberg et al. 64 noted that, of all avail able guidelines, Nature Reviews | Urology they were most influenced by those of the USPSTF. Within the Johns Hopkins Community Physicians practice, 49.2% of primary-care providers agreed or strongly agreed with the recommendation, 36.0% disagreed or strongly disagreed and the rest neither agreed nor disagreed 72 . However, despite these sentiments, 37.7% said they would not change their screening practices, and only 1.8% expected to cease routine PSA testing; 21.9% stated they were much less likely to screen and 38.6% were somewhat less likely. Interestingly, Pollack et al. 72 found that clinicians who were active advocates of PSA screening were less likely to abandon the practice than those who, after a discussion of benefits and risks, allowed their patients to decide (11.9% versus 32.6%; P = 0.01). Furthermore, the national cross-sectional survey by Tasian and colleagues 71 revealed that only 51% of the 3,010 primary-care providers discussed PSA screening with patients, but 64% reported ordering the test 71 . Finally, Rosenberg and colleagues' (REF. 64) survey at the 2015 American Academy of Family Practice annual meeting showed that 22.9% of respondents did not recommend PSA screening 64 . Of the 78% that did, 50% began at 45 years and 41% at 55 years. Overall, although these data illustrate mixed views towards and mixed compliance with the 2012 USPSTF recommendation, a complete abandonment of PSA screening, as the guideline suggests, has certainly not occurred.
Effects on long-term outcomes
At present, only 4 years have passed since the USPSTF issued a D grade to PSA screening. Thus, whether this recommendation will have an effect on prostate-cancerrelated mortality is, as yet, uncertain. At one institution, the total number of radical prostatectomies performed decreased by 35% and the proportion of Gleason score 6 diagnoses decreased from 24% to 12% (P <0.01) in the first 3 years after the recommendation in 2012, compared with the 3 years prior. At the same time, the post-2012 group had a significantly higher proportion of Gleason scores 4 + 3 = 7 (from 8.4% to 13.2%, P = 0.01) and 8 (12.5% to 20.6%, P = 0.04), and extra prostatic extension (P < 0.01); however, whether these effects are due to reduced PSA screening or improved patient selection is difficult to determine 73 . Similarly, within a network of radiation oncology clinics, the number of men with prostate cancer presenting for radiation-oncology care decreased during 2007-2013. The numbers of lowrisk and intermediate-risk patients decreased, but no short-term changes in high-risk or metastatic disease were observed, and longer-term data are not yet available 74 . The USPSTF 2012 recommendation might also have influenced practice patterns in other continents, with steady nationwide declines in the rates of PSA testing, prostate biopsy, and prostatectomy observed in Australian Medicare data 75 . Nevertheless, mathematical simulation models have been developed to estimate the number of future prostate-cancer-related deaths that might have been avoided with early detection and treatment with curative intent. Under current screening rates, an estimated 710,000-1.12 million men would be overdiagnosed between 2013 and 2025, but 36,000-57,000 deaths from prostate cancer would be prevented 76, 77 . Abandonment of PSA screening would prevent all cases of overdiagnosis, but fail to prevent 100% of avoidable deaths, leading to a 13%−20% increase in prostate-cancer-related deaths. Furthermore, incidence of metastatic disease would increase more than twofold. Even if screening were restricted to men <70 years, a predicted 13,000-22,000 additional deaths would occur, and the incidence of metastatic disease at diagnosis would increase 46-57%.
Proponents of the USPSTF recommendation
Since the USPSTF draft recommendation in late 2011, whether their blanket rejection of PSA screening was justified has been hotly debated. Those who support the USPSTF cite the ERSPC and PLCO trials: the former found a moderate decrease in prostate-cancer-specific mortality and the latter found no decrease at all 1, 2, 78, 79 . However, the PLCO trial's power to detect a difference in prostate cancer mortality between trials arms was limited by excessive opportunistic PSA testing in the control arm 80, 81 . Michael LeFevre, a member of the USPSTF, pointed out that, although the benefits might not be fully clear owing to mixed results, the harms of screening are well-defined -overdiagnosis, biopsy complications, and overtreatment 78 . Barry and Nelson 82 noted the lack of population-based data linking the recommendation to increased advanced-stage disease, and Richard Ablin 79 has stated that PSA is inadequate as a diagnostic marker for prostate cancer because it lacks specificity. Thus, the USPSTF recommendation might lead to development of specific biomarkers for prostate cancer that are superior to PSA. In a report in the New England Journal of Medicine, Brett and Ablin 83 pointed out that other guidelines emphasize shared decision-making between patients and practitioners, but the less-than-definitive results from the randomized clinical trials in prostate cancer have made it difficult to derive any conclusive benefit from screening.
Opponents of the USPSTF recommendation
The USPSTF's guideline has been blamed for creating confusion among patients and clinicians alike 25, 64, 82, [84] [85] [86] [87] , and more physician education is warranted 40 . The USPSTF recommends against PSA screening in all men, but simultaneously states that "clinicians should understand the evidence but individualize decision making to the specific patient or situation. " 3 These statements are directly conflicting. Editorializing in The Journal of Urology, Samir Taneja wrote: "The mass confusion regarding interpretation of guidelines and application in practice is the result of a recommendation that is not particularly intuitive. How does one prevent prostate cancer death if one is not looking for prostate cancer?" (REF. 88) In response to the October 2011 draft, the AUA responded by saying that by disparaging the PSA test, the USPSTF is doing a great disservice to the men worldwide who might benefit from receiving it 89 . Moreover, clinicians and researchers have challenged the recommendation because the USPSTF excluded relevant data. Catalona and Walsh 86, [90] [91] [92] note the failure to consider epidemiological data from the PSA era, which show a 40% reduction in prostate-cancer mortality and a 75% decline (from 21% to 4%) in advanced-stage disease on diagnosis 86, [90] [91] [92] . The USPSTF also stressed the morbidity associated with radical prostatectomy and radiotherapy, yet overlooked the morbidity associ ated with advanced-stage disease, such as spinal cord compression 82, 93 . In addition, although their decision was largely based on the results of the PLCO trial, the USPSTF did not account for methodological limitations within that trial, and more recent assessment of the data used in PLCO has suggested that the rate of screening in the control arm was actually higher than that in the screening arm of the study 80 . Given these limitations, researchers have questioned why the USPSTF did not consider model ling data as evidence of the benefits of screening. Etzioni and Thompson 94 claimed modelling data was necessary for obtaining a complete picture about PSA screening, as the limitations and variability within the two large trials could have dampened its true benefits 94 . Using statistical models, they demonstrated that extrapolation of the ERSPC results yielded a fivefold greater benefit in favour of screening 95 , whereas model ling of the PLCO trial revealed insufficient statistical power to detect differences between the screening and control arms 94, 95 .
The future Several researchers have suggested that the USPSTF ought to upgrade their recommendation for PSA screening to a grade C 96, 97 : that "clinicians may provide this service to selected patients depending on individual circumstances. However, for most persons without signs or symptoms there is likely to be only a small benefit from this service" (REF. 3 ). McNaughton-Collins and Barry 96 have explained that a grade C recommendation is more fitting, considering the benefit of screening noted in the ERSPC trial, and -unlike a blanket rejection that might influence physicians to abandon the practice altogether -it would involve the patient in the decision of whether or not to screen and might also decrease the haphazard screening of men who are unlikely to benefit. Volk and Wolf 97 concur: although overtreatment is a disadvantage of PSA screening, some men are willing and eager to accept the potential adverse effects of treatment to eradicate their cancer, regardless of risk. However, a blanket rejection of PSA screening with a D grade wholly eliminates the patient from the discussion, and a C grade would restore patient participation and facilitate individualized shared decision-making. All contemporary professional guideline groups agree that PSA screening ought to take place in the context of shared decision-making between an individual man and his health-care provider 10 . However, evidence suggests that shared decision-making, as currently practiced, is sub-par [98] [99] [100] [101] [102] [103] . One in four primary-care providers order the PSA test without discussing it with their patient 101 , or do not engage in shared decision-making as recommended; in fact, studies suggest that only 10-33% of patient-provider communications cover essential domains of shared decision-making 102, 103 . Using data from the 2013 Health Information National Trends Survey, Meyer et al. suggested providing differential counselling according to sociodemographic factors, with increased odds of being counselled on the potential adverse effects of treatment for older men and men with a prior cancer history, yet these men were also those most likely to undergo PSA testing 41 . More research is certainly needed on the practical aspects of implementing shared decision-making at the point of care.
Conclusions
Widespread decreases in PSA testing rates have been observed since the 2012 USPSTF Grade D recommendation, with the magnitude of this change varying between cohorts, age groups, and physician specialty. Whereas screening rates in men >75 years continued to declinein part due to the USPSTF's 2008 recommendation -and concurrent decreases were also noted in younger men, current screening rates suggest that PSA screening is still a common practice in the USA. An aggregated body of available evidence now suggests that, in the years following the 2012 USPSTF recommendation, fewer younger men -who could benefit from being screened -are being tested (underscreening), while a substantial proportion of older men are still being screened, most likely without benefit (overscreening). Men at high risk of developing prostate cancer also received less screening 18, 27 , possibly as a consequence of a lack of special recommendation for this population. Although some physicians are inclined to adopt risk-stratified screening practices through further clinical work-up to ascertain disease aggressiveness and longer screening intervals for patients with low PSA levels 32, 46 , others have opted to indiscriminately abandon the practice altogether, as recommended.
Furthermore, differences in PSA testing rates and attitudes among physicians of various specialties elucidate the ways in which different physicians might be interpreting the recommendations. Primary-care physicians, who are strongly influenced by the USPSTF's recommendations 64, 71, 72 , were more accepting of the guideline than urologists 28 . The guidelines also had differential effect on clinical administration of PSA testing among urologists and radiation oncologists 33 . These differences suggest that physicians have not uniformly translated the guidelines into a change in clinical practice.
An overall decrease in prostate cancer incidence has been noted in the years following the 2012 USPSTF recommendation 19, 22, 48, 58 . PSA screening favours detection of low-risk tumours that are often confined within the prostate, so a systematic reduction of screening has also meant that rates of low-risk cancer have decreased 19, 48, 58 . This decline might be indicative of the intended effect of the USPSTF recommendation -that is, reducing rates of overdiagnosis and overtreatment of low-risk cancers. However, a simultaneous reduction in the detection of intermediate-risk and high-risk cancers significantly hinders the likelihood of cure by delaying timely diagnosis and treatment.
In accordance with reduced rates of screening and prostate cancer incidence, biopsy rates at some institutions have declined simultaneously 42, 43, [47] [48] [49] [50] [51] .
One explanation is that apprehension towards PSA screening generated by this guideline has led to fewer asymptomatic, disease-free men receiving prostate biopsies. However, this change might concurrently result in more men with prostate cancer being diagnosed at later stages, once their cancers have precipitated symptoms that would justify clinical investigation. Indeed, increased rates of advanced disease upon detection were noted 43 , characterized by increased prebiopsy PSA levels 39, 43, 45 , higher Gleason scores 43, 51, 65 , and more advanced clinical TNM stage 45, 47 . This risk-group stage migration towards higher risk, more advanced tumours might be indicative of improved selection of men for prostate biopsy. However, notable decreases in prostate cancer incidence across all risk groups are concerning 48 , as -assuming no change in the natural history of the disease -they might indicate that high-risk cancers are evading detection.
Many physicians were aware of the USPSTF recommendation, but only a small percentage stated intent to follow the guideline subsequent to its release and eliminate PSA screening from their practice 64, 71, 72 . However, the actual data regarding the nationwide decreases might suggest otherwise. Similarly, patients who were informed about the guideline agreed with it but intended to continue screening 68, 69 . Despite the USPSTF, patients are still choosing to receive the PSA test.
In a short correspondence published in the Journal of Urology, David Penson raises concerns that "we will soon return to the pre-PSA era, when men presented with locally advanced and/or metastatic disease and our only treatment option was androgen deprivation therapy and palliative care". Accordingly, he has called for abandoning the 'one size fits all' approach to screening in favour of more personalized screening strategies, in order to maximize the benefits and reduce the harms of screening 104 . Overall, in the years since the 2012 USPSTF recommendation against PSA screening, PSA testing rates and prostate cancer incidence have decreased. The long-term consequences of this rejection of PSA screening have yet to be elucidated. As of October 2016, the USPSTF is in the process of reviewing the evidence and preparing to update their recommendation. Since the last evidence review in 2011, the evidence regarding who, when, and how often to screen, and how to achieve a better balance between harms and benefits has grown considerably. We are pleased to see that the research plan for the systematic review of the evidence that the USPSTF is currently undertaking includes risk-stratified approaches on the individual level, including addressing the question of whether the effectiveness of PSA-based screening varies by subpopulation and risk factor, such as age, race, ethnicity, family history, and clinical risk assessment 105 .
